Fortress Biotech, Inc. (FBIO): Nasdaq/NYSE listing notice — Fortress Biotech receives Nasdaq bid price deficiency notice; 180-day cure period through May 1, 2023

Fortress Biotech, Inc.

Received Nasdaq letter on Oct 31, 2022 for bid price below $1.00 for 30 consecutive business days.
Non-compliance with Nasdaq Listing Rule 5550(a)(2) for common stock (FBIO).
180-day grace period through May 1, 2023; must close at $1.00+ for 10 consecutive days to cure.
If not cured, may be eligible for another 180 days if meets initial listing criteria and market value requirement.
Company evaluating options to remedy bid price deficiency; no decision made yet.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Fortress Biotech, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

October 31, 2022, Fortress Biotech, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), had closed below $1.00 per share for 30 consecutive business days and, as a result, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which sets forth the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq’s notice has no immediate effect on the listing of the C

View on SEC.gov

Browse all listing & compliance notices →

Fortress Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-114895

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.